Bisphenol S (BPS) shows the potential for increasing the aggressiveness of breast cancer through its behaviour, as an endocrine-disrupting chemical.

‘If a woman has a mutated BRAC1 gene and uses products containing BPS, her risk for developing breast cancer may increase further.’

The findings suggest that BPS may cause breast cancer to become more aggressive. The results, which tested BPS in human breast cancer cells, is scheduled to be presented at ENDO 2017, the Endocrine Society's 99th annual meeting in Orlando, Florida. "Despite hopes for a safer alternative to BPA, studies have shown BPS to exhibit similar estrogen-mimicking behaviour to BPA," said the study's principal investigator Sumi Dinda. Their study confirmed that BPS acts like estrogen in breast cancer cells, Dinda said, adding, "So far, BPS seems to be a potent endocrine disruptor." 




The researchers studied the effects of BPS on estrogen receptor-alpha and the BRCA1 gene. Using two commercially available breast cancer cell lines obtained from women with estrogen-receptor-positive breast cancer, the team exposed the cancer cells to varying strengths of BPS or to an inactive substance as a control.
They also treated the breast cancer cells with estradiol (estrogen) and found that BPS acted like estrogen in multiplying breast cancer cells. Compared with the control, BPS heightened the protein expression in estrogen receptor and BRCA1 after 24 hours, as did estrogen. The results indicated that after a six-day treatment with BPS, the breast cancer cells in both cell lines reportedly increased in number by 12 percent at the lowest dose (4 micromolars) and by 60 percent at 8 micromolars.
Although further study of BPS in breast cancer cells is needed for confirmation, he suggested that "if a woman has a mutated BRAC1 gene and uses products containing BPS, her risk for developing breast cancer may increase further."
Source-ANI